Communiqués Hanall Biopharma Co., Ltd.

Actions

A009420

KR7009420001

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
34 150 ^KRW	+3,96%		+8,24%	-22,91%

14/05	Hanall Biopharma Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
03/05	HanAll Biopharma annonce le lancement de l'étude de phase III VELOS-4, randomisée, en double aveugle et contrôlée par véhicule, évaluant le tanfanercept dans le traitement de la sécheresse oculaire	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases	29/05	AQ
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies	28/05	AQ
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	13/06/23	AQ
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	13/06/23	AQ
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01/05/23	AQ
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth	30/03/23	AQ
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program	16/03/23	AQ
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities	13/02/23	AQ
Immune Thrombocytopenia Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain	09/12/22	AQ
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update	16/11/22	AQ
HanAll Biopharma's Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China	11/10/22	AQ
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update	01/08/22	AQ
Hanall Biopharma : Decision on Disposal of Treasury Stock	23/06/22	PU
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative	12/04/22	AQ
HanAll Biopharma Launches KRW 10 billion Share Buyback Program	15/03/22	AQ
Hanall Biopharma : Decision on Calling Shareholders' Meeting	14/03/22	PU
Hanall Biopharma : Organization of Investor Relations Event	26/01/22	PU
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update	24/01/22	AQ
Hanall Biopharma : Interim Report on Business Performance (Fair Disclosure)	19/01/22	PU
Hanall Biopharma : Changesof 30% or More in Salesor Profits/Losses(15% or More in the Case of Large-sized Corporations)	19/01/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Hanall Biopharma Co., Ltd.

Actions

A009420

KR7009420001

Communiqués

Filtres